May 17, 2017 / 7:07 AM / 2 months ago

BRIEF-Kaken Pharmaceutical receives marketing approval for Jublia in S.Korea

1 Min Read

May 17 (Reuters) - Kaken Pharmaceutical Co Ltd :

* Says product Jublia, topical formulation for Onychomycosis, has received marketing approval in South Korea

Source text in Japanese: goo.gl/bq6tyA

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below